Insider Selling: Amyris Inc. (AMRS) Major Shareholder Sells 2,300,000 Shares of Stock
Amyris Inc. (NASDAQ:AMRS) major shareholder (Mauritius) Pte Ltd Maxwell sold 2,300,000 shares of the firm’s stock in a transaction that occurred on Monday, October 17th. The shares were sold at an average price of $0.83, for a total value of $1,909,000.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Shares of Amyris Inc. (NASDAQ:AMRS) traded up 8.98% during mid-day trading on Tuesday, reaching $0.97. The company’s stock had a trading volume of 3,042,248 shares. The firm’s market cap is $227.97 million. Amyris Inc. has a one year low of $0.31 and a one year high of $1.85. The firm’s 50 day moving average is $0.53 and its 200 day moving average is $0.59.
Amyris (NASDAQ:AMRS) last released its earnings results on Thursday, August 4th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.06. The firm earned $9.60 million during the quarter, compared to analyst estimates of $15.23 million. During the same period in the previous year, the company earned ($0.47) earnings per share. Amyris’s revenue was up 23.1% on a year-over-year basis. On average, equities analysts anticipate that Amyris Inc. will post ($0.20) earnings per share for the current fiscal year.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/18/insider-selling-amyris-inc-amrs-major-shareholder-sells-2300000-shares-of-stock.html
Several institutional investors have recently added to or reduced their stakes in AMRS. Vanguard Group Inc. raised its stake in Amyris by 22.4% in the second quarter. Vanguard Group Inc. now owns 1,701,779 shares of the company’s stock valued at $766,000 after buying an additional 311,142 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in Amyris during the first quarter valued at approximately $269,000. Finally, Geode Capital Management LLC raised its stake in Amyris by 11.6% in the first quarter. Geode Capital Management LLC now owns 298,669 shares of the company’s stock valued at $331,000 after buying an additional 30,958 shares during the last quarter. 35.68% of the stock is currently owned by hedge funds and other institutional investors.
A number of research analysts recently weighed in on the company. Zacks Investment Research raised Amyris from a “hold” rating to a “buy” rating and set a $0.50 price objective for the company in a research report on Tuesday, August 9th. Singular Research reiterated a “buy” rating and set a $2.80 target price on shares of Amyris in a research note on Wednesday, September 28th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $2.66.
Amyris Company Profile
Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.
Receive News & Ratings for Amyris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris Inc. and related companies with MarketBeat.com's FREE daily email newsletter.